Opinion|Videos|October 7, 2024
Current Treatment Options for Dravet Syndrome
Author(s)M. Scott Perry, MD
Key Takeaways
- The primary treatment goal for Dravet syndrome is reducing seizure frequency and severity while improving quality of life and minimizing side effects.
- Initial treatments for Dravet syndrome include valproate and clobazam, which are effective in managing seizures.
The panelist discusses how the goal of Dravet syndrome treatment is to reduce seizure frequency and severity, typically starting with initial treatments like valproate and clobazam and potentially escalating to combination therapies including options such as cannabidiol, with the overall aim of improving patients’ quality of life and developmental outcomes
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the goal of treatment for Dravet syndrome?
- Please describe the recommended initial treatments for Dravet syndrome.
- Valproate
- Clobazam
- Please describe the recommended initial treatments for Dravet syndrome.
- Please describe treatment options that are available as escalation therapy in combination with initial treatments for Dravet syndrome.
- Stiripentol
- Cannabidiol
- Fenfluramine
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5